POLITICO
·
UK–US agreement removes tariffs on UK pharmaceuticals
Zero-tariff access linked to NHS policy changes
Change
The UK and US agreed to eliminate tariffs on UK pharmaceuticals for at least three years alongside NHS pricing policy changes.
Why it matters
The agreement increases NHS spending commitments and limits rebate mechanisms, altering cost-control tools for medicines.
Implications
- — Pharma exporters gain tariff-free access — competitiveness improves
- — NHS cost controls constrained — spending pressure rises
Who is affected
- — Pharmaceutical companies
- — Healthcare payers
What to watch
- — Extension beyond three-year window